biotech flying under the radar...results due

Well here is one for the early birds, CBZ listed early this year as 50c float and is currently just under 20c.

The co never raised enough initially and the market has known they would need to do raisings to complete the trials.

Raisings are now out of the way and results will come in the first 1/4 for arthritis, psoriasis and multiple
sclerosis (MS). Other diseases will also be trialled.

Current trials to date have been very promising, this a multi billion dollar market.

I would urge people to look at the calibre of directors involved in this one.

I think the stock will rise from here firstly due to the raisings out of the way and secondly in anticiaption of the results, I have been advised to hold these by my broker who expects close to $1 on positive results then it can then start discussions with multinational pharmacompanies about licensing XToll? .

2010 ie next few months-

?Pre-IND meeting with FDA
?CMC scale-up (manufacturing), based on funding
?Prepare for long term toxicology, based on funding
2011
?Complete RA clinical trial
?Conclude a licensing transaction or collaboration with a partner


Existing RA drugs generate significant income for global pharmaceutical companies -the top 3 drugs generated a combined income of approximately US$19 billion in 2009.
These drugs however only work for 60% to 70% of patients and they also have significant safety issues.

CBiohas granted an option to Novo Nordisk (a global top 20 pharmacompany with over 29,000 employees)
This Option allows Novo to have the first right to negotiatea licensing agreement on or before the completion of the current clinical trial. If CBiois unhappy with the terms CBiocan transact with another pharmacompany at that time.

The manufacturing cost of goods for XToll?is very low compared with the current registered RA drugs

Total patients enrolled ?150
All patients have now been recruited into the trial
Patients that went from trial to long term follow up ?above 85%
Rheumatologist's feedback ?as good as other registered drugs on the market